5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Market is segmented by Therapeutic Class (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors), Anti-Platelets and Others) and Geography
Fastest Growing Market:
Lifestyle diseases and their chronic nature is among the pivotal reason for the high cardiovascular-related disorders globally. As per the Nesia Foundation Hospital, globally, about 14.2 million people between the age group 30-69 years, die prematurely from lifestyle disorders such as diabetes, arteriosclerosis, high cholesterol, stroke, nephritis, cancer, and several others. As per several published data on lifestyle-related diseases, women have more atypical signs of heart attack more often than men. In addition, in several cases, there is increased misdiagnosis or delayed diagnosis which eliminate the likeliness to receive immediate life-saving treatment of primary angioplasty and stents. The increasing burden of lifestyle diseases directly impacts the socio-economic aspects of nations globally, where appropriate actions for their management is the need of the moment. Thus, increasing burden of lifestyle diseases majorly drives the demand and need for angina pectoris drugs market.
As per the scope of the report, Angina pectoris refers to a strangling or pressure-like pain caused by cardiac ischemia. Angina drugs are the initial treatment of angina pectoris. The antianginal drugs recommended for initial treatment are β blockers and calcium channel blockers, which reduce myocardial ischemia by heart rate reduction and vasodilatory mechanisms, respectively. Either or both of these drug classes should be prescribed, together with a short-acting nitrate for prompt alleviation of angina attacks.
|By Therapeutic Class|
|Calcium Channel Blockers|
|Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)|
Report scope can be customized per your requirements. Click here.
Beta blockers work by blocking the effect of adrenaline on the heart by providing benefits such as Slowing of the heart rate and reducing the force of heart muscle contraction. In patients with stable angina caused by CAD, beta blockers are considered first-line therapy. Beta Blockers has the smallest share in the market as the majority of beta-blocker drugs are predominately generic with key patent expirations impacting GlaxoSmithKline’s Coreg and AstraZeneca’s Toprol. Post Pfizer’s Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic as well.
To understand key trends, Download Sample Report
North America dominates the Angina Pectoris Drugs market due to the established healthcare infrastructure, increased adoption of therapeutics and presence of key manufacturers in the U.S are responsible for its large share. Ischaemic heart disease is a major cause of death and disability worldwide, while angina represents its most common symptom. It is estimated that approximately 9 million patients in the USA suffer from angina and its treatment is challenging. Moreover, increasing incidence of cardiac disorders due to the sedentary lifestyle and favorable regulatory initiatives are fueling the market growth.
To understand geography trends, Download Sample Report.
Some of the prominent industry players operating in total Angina Pectoris Drugs market include Amgen, Bayer AG, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline Plc and Merck & Co., Inc. Development of advanced products for better outcomes and rigorous marketing are some of the competitive strategies adopted by market players.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Lifestyles Diseases
4.2.2 Technological Advancements towards Personalized Cardiovascular Medicines
4.2.3 Augmentation of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Adoption of Minimally Invasive Surgeries
4.3.2 Side Effects Associated with Certain Drug Classes
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Therapeutic Class
5.1.1 Beta Blockers
5.1.2 Calcium Channel Blockers
5.1.4 Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
5.2.1 North America
22.214.171.124 Rest of Europe
5.2.3 Asia Pacific
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.2.4 Middle East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle East and Africa
5.2.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Bayer AG
6.1.3 Eli Lilly and Company
6.1.4 Gilead Sciences
6.1.5 GlaxoSmithKline Plc.
6.1.6 Merck & Co., Inc.
6.1.7 Novartis AG
6.1.8 Otsuka Pharmaceutical Co. Ltd
6.1.9 Pfizer Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments